Cecilia Abacan-BelmonteOctober 20, 2024InhaleRx Ltd (ASX: IRX) (‘InhaleRx’ ‘IRX’ or ‘the Company’), an Australian healthcare company developing unique drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to announce that it has entered into a significant funding agreement with Clendon Biotech Capital Pty Ltd (‘Clendon Biotech Capital’).

Cecilia Abacan Belmonte2024Innairex Ltd（ASX:IRX）（“Innairex”，“IRX”或“该公司”）是一家开发独特药物器械产品以解决疼痛管理和心理健康领域未满足的医疗需求的澳大利亚医疗保健公司，很高兴地宣布，它已与Clendon Biotech Capital Pty Ltd（“Clendon Biotech Capital”）签订了一项重要的融资协议。

This strategic partnership will provide the funding to cover all direct costs associated with the Phase 1 & 2 clinical development of the Company's key projects - IRX-211 and IRX-616a. Highlights:Secured Funding: InhaleRx has secured a funding facility of up to $38.5 million from Clendon Biotech Capital to fully cover the clinical trial costs, including the associated non-clinical work and trial drug manufacturing costs for the IRX-211 and IRX-616a drug development plans through to the completion of Phase 2 clinical trials.Clinical Progress: This funding will enable InhaleRx to move forward with its clinical development plans for IRX211 and IRX616a, including non-clinical data.

。亮点：有保障的资金：InHoraRx已从克伦登生物技术资本获得高达3850万美元的资金，以完全支付临床试验成本，包括IRX-211和IRX-616a药物开发计划的相关非临床工作和试验药物制造成本，直至完成第二阶段临床试验。临床进展：这笔资金将使In吸入Rx能够推进其IRX211和IRX616a的临床开发计划，包括非临床数据。

It will also enable IRX to address the requirements of the US Food & Drug Administration (‘FDA’) relevant to its recent IRX-616a Investigational New Drug (‘IND’) application.Focus on Transformational Therapeutics: With this strategic support, InhaleRx is well positioned to accelerate the development of breakthrough inhaled therapies for patients with unmet medical needs.The funding agreement provides InhaleRx access to up to $38.5 million in funding, which is expected to allow the Company to reach the Phase 3 pivotal stage for both IRX-211 and IRX-616a within the next 2-3 years.

它还将使IRX能够满足美国食品和药物管理局（“FDA”）对其最近的IRX-616a研究性新药（“IND”）申请的要求。专注于转化疗法：在这一战略支持下，Innairex处于有利地位，可以加速为未满足医疗需求的患者开发突破性的吸入疗法。该融资协议为in吸入Rx提供了高达3850万美元的资金，预计该公司将在未来2-3年内进入IRX-211和IRX-616a的第三阶段关键阶段。

The facility allows for the drawdown of funding as eligible expenditure is incurred.Further details of the Clendon Biotech facility.

该贷款允许在发生符合条件的支出时提取资金。克伦登生物技术工厂的更多细节。